Pfizer (PFE)
(Delayed Data from NYSE)
$28.55 USD
-0.21 (-0.73%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $28.59 +0.04 (0.14%) 7:58 PM ET
2-Buy of 5 2
A Value F Growth B Momentum C VGM
Pfizer (PFE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.11 | $45.00 | $27.00 | 15.13% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Pfizer comes to $33.11. The forecasts range from a low of $27.00 to a high of $45.00. The average price target represents an increase of 15.13% from the last closing price of $28.76.
Analyst Price Targets (19)
Broker Rating
Pfizer currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 2.19 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, nine are Strong Buy, representing 42.86% of all recommendations. A month ago, Strong Buy made up 38.1%, while Buy represented 4.76%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 8 | 8 | 8 | 9 |
Buy | 0 | 1 | 1 | 1 | 1 |
Hold | 12 | 12 | 12 | 12 | 12 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.14 | 2.19 | 2.19 | 2.19 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Daiwa America | Narumi Nakagiri | Moderate Buy | Strong Buy |
8/6/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/1/2024 | Argus Research Corp. | David A Toung | Hold | Hold |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | Goldman Sachs | Chris Shibutani | Strong Buy | Strong Buy |
7/31/2024 | UBS | Trung Huynh | Hold | Hold |
7/31/2024 | Wells Fargo Securities | Mohit Bansal | Hold | Hold |
6/17/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/13/2024 | Atlantic Equities | Steven K Chesney | Hold | Hold |
5/2/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
5/2/2024 | SVB Securities | David Risinger | Hold | Hold |
4/10/2024 | Berenberg Bank | Kerry Holford | Not Available | Hold |
4/1/2024 | Cowen & Co. | Steve M Scala | Hold | Hold |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/23/2024 | Guggenheim Securities | Vamil Divan | Not Available | Strong Buy |
10/23/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
10/17/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.19 |
# of Recs in ABR | 21 |
Average Target Price | $33.11 |
LT Growth Rate | 10.70% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 65 of 253 |
Current Quarter EPS Est: | 0.62 |